120
Participants
Start Date
December 9, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2026
TQB3002 Tablets
TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
NOT_YET_RECRUITING
Shanghai Pulmonary Hospital, Shanghai
NOT_YET_RECRUITING
Jiangsu Province Hospital, Nanjing
NOT_YET_RECRUITING
The First Affiliated Hospital Of Nanchang University, Nanchang
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
NOT_YET_RECRUITING
Sichuan Cancer Hospital, Chengdu
NOT_YET_RECRUITING
Mianyang Central Hospital, Mianyang
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY